Sanofi-Aventis: A Mix of News

With the company providing so much information, there are a lot of possible interpretations of whether Sanofi-Aventis (NYSE: SNY  ) had a "good" quarter. While I'd suggest the financial performance was pretty respectable, the clinical trial insights were more mixed.

Sales for the second quarter rose 6.5% on a reported basis and 10.1% on a "comparable" basis that adjusts for the Aventis merger and foreign currency effects. Margins were quite solid once again: Gross margin improved to nearly 79%, and operating margin climbed to 33.7%. Adjusted net income rose by 26%.

The company's top drugs led the way again, with the top 15 compounds bringing revenue growth of 16.2% in the quarter and making up more than 60% of the company's total. Market-leading drugs like Lovenox, Plavix, and Lantus were all quite strong and posted double-digit growth. The vaccine business also had a good quarter, as a new meningitis/pneumonia vaccine helped push sales up more than 13%.

Sanofi-Aventis generated more than $3.5 billion in free cash flow (before dividends) and has managed to repay close to $2 billion in debt so far this year. Based on the strong results, management raised earnings growth guidance for this year to at least 20%.

The clinical side of the business was less stellar. Sanofi-Aventis announced that it was dropping two compounds that were in phase 2-b testing (pranalcasan for arthritis and osanetant for schizophrenia). The company also announced mixed data from a phase 3 depression trial (the European study showed decent efficacy, but the North American study did not), and it's quite possible that another phase 3 study may be required before approval.

On a more positive note, the company had better success in trials studying insomnia, smoking cessation, and cancer. Investors should also remember that Sanofi-Aventis is awaiting Food and Drug Administration approval for Acomplia for obesity and smoking; Exubera, which is inhaled insulin, with Pfizer (NYSE: PFE  ) and Nektar (Nasdaq: NKTR  ) as partners; dronedarone for atrial fibrillation; Alvesco for asthma; and a longer-acting formulation of Ambien, for insomnia.

These late-stage drugs (as well as the 35 compounds in phases 2b or 3 testing) will be important. Sanofi-Aventis faces the threat of losing patent protection for Lovenox and Plavix, and should that happen, it would need these new drugs to maintain growth.

I won't make the case that Sanofi-Aventis is dirt-cheap or significantly undervalued. Stocks like Merck (NYSE: MRK  ) , GlaxoSmithKline (NYSE: GSK  ) , and AstraZeneca (NYSE: AZN  ) are all cheaper, just to name three. But I do believe that Sanofi-Aventis has an appealing late-stage pipeline and the wherewithal to produce much better growth than the average pharmaceutical company over the next few years. Growth or value? It's an age-old question, but I'm continuing to stick with growth in this particular case.

For more healthy pharmaceutical Takes:

Pfizer is a Motley Fool Inside Value selection; Merck is an Income Investor pick. For more investment ideas, tryany of our newsletters.

Fool contributor Stephen Simpson owns shares of Sanofi-Aventis. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 495823, ~/Articles/ArticleHandler.aspx, 9/21/2014 12:27:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement